E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10015488 |
E.1.2 | Term | Essential hypertension |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Comparar la eficacia de 300 mg de aliskiren una vez al día con 150 mg de aliskiren dos veces al día para reducir la media de presión arterial diastólica ambulatoria (MPADA) durante 24 horas, desde la situación basal al final del período 2 del estudio (semana 6) en pacientes con hipertensión esencial. |
|
E.2.2 | Secondary objectives of the trial |
Evaluar la eficacia de: 300mg de SPP100 1vez/día vs 150mg 2veces/día para reducir MPADA y MPASA las 3últimas horas del período de dosis de 24h. De 300mg de SPP100 1vez/día vs 150mg 2 veces/día para reducir MPAS durante 24h. De en términos de la reducción de la MPADA durante 24h. y de la MPASA,de 300mg de SPP100 1vez/ día desde el final del período2 hasta fin de estudio, en los pacientes tratados con 150mg de SPP100 dos veces/día durante el período2. De en términos de reducción de la MPADA durante 24h y de la MPASA, de 300mg de SPP100 1vez/día desde el final del período2 hasta el fin del estudio, en los pacientes con 300mg de SPP100 1vez/día durante el período2.De en términos de la reducción de mPADs y la mPASs, de 300mg de SPP100 1vez/día vs 150mg de SPP100 2 veces/día.La proporción de pacientes que llega al objetivo de control de PA.La proporción de pacientes que consigue el objetivo de control de PA en cada brazo de tratamiento. Y el perfil de seguridad/tolerabilidad de SPP100.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female outpatients 18 years of age and older. - Patients with a diagnosis of uncomplicated essential hypertension; newly diagnosed or who have not received antihypertensive medication within 4 weeks of Visit 1 must have an office cuff msDBP ≥ 100 mmHg and ≤ 110 mmHg at Visit 1. - Patients receiving antihypertensive treatment must have a cuff msDBP of ≥ 95 mmHg and ≤ 110 mmHg at Visit 1. - Prior to the randomization, all patients must have an office cuff msDBP ≥ 100 mmHg and ≤ 110 mmHg. 4. Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent). |
|
E.4 | Principal exclusion criteria |
For full list, see protocol Patients with any of the following at Visit 1 or 2 at which the patient will be excluded from participation in the study. 1. Previously treated with aliskiren in the last six months or have previously participated in an aliskiren trial in this development program within the last six months and who qualified to be randomized or enrolled into the active drug treatment period. 2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (≥ 5 mIU/ml). 3. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception (implantable, patch, and oral), and double-barrier methods (if accepted by local ethics committee). Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation. 4. Patients with an office cuff blood pressure of msDBP ≥ 112 mmHg and/or msSBP ≥ 200 mmHg 5. History or evidence of a secondary form of hypertension. 6. Previous or current diagnosis of heart failure (NYHA Class II, III and IV). 7. History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI). 8. Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1. 9. Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled as determined by local country criteria. It is recommended that patients currently being treated for diabetes mellitus be on a stable dose of antidiabetic medication for at least 4 weeks prior to Visit 1. 10. Current angina pectoris requiring pharmacological therapy (the use of nitrates for the treatment of angina will be allowed). 11. Second or third degree heart block without a pacemaker. 12. Potentially life threatening arrhythmia during the 12 months prior to Visit 1. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Comparar la eficacia de 300 mg de aliskiren una vez al día con 150 mg de aliskiren dos veces al día para reducir la media de presión arterial diastólica ambulatoria (MPADA) durante 24 horas, desde la situación basal al final del período 2 del estudio (semana 6) en pacientes con hipertensión esencial. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 51 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 1 |